Adult vaccination coverage for the vaccine-preventable respiratory diseases (influenza, COVID-19, pneumococcal pneumonia and pertussis) is sub-optimal. For the one in three Australians living with a lung disease, these infections increase their risk of symptom exacerbation, lung function deterioration, hospitalisation and death. This page summarises the recommendations from the Australian Technical Advisory Group on Immunisation (ATAGI), including the new vaccine recommendation for RSV for Australians over 60 years of age.